|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chaturvedi AK, Anderson WF,
Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS,
Bray F and Gillison ML: Worldwide trends in incidence rates for
oral cavity and oropharyngeal cancers. J Clin Oncol. 31:4550–4559.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ganguly R, Hong CS, Smith LG, Kornblum HI
and Nakano I: Maternal embryonic leucine zipper kinase: Key kinase
for stem cell phenotype in glioma and other cancers. Mol Cancer
Ther. 13:1393–1398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chung S, Suzuki H, Miyamoto T, Takamatsu
N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y and Matsuo Y:
Development of an orally-administrative MELK-targeting inhibitor
that suppresses the growth of various types of human cancer.
Oncotarget. 3:1629–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung S and Nakamura Y: MELK inhibitor,
novel molecular targeted therapeutics for human cancer stem cells.
Cell Cycle. 12:1655–1656. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
simpleClinicalTrials.govPhase 1 study of OTS167 in
patients with solid tumors. https://clinicaltrials.gov/ct2/show/NCT01910545July
29–2013
|
|
7
|
simpleClinicalTrials.govPharmacological study of
intravenous OTS167 in patients with refractory or relapsed acute
myeloid leukemia, acute lymphoblastic leukemia, advanced
myelodysplastic syndromes, advanced myeloproliferative neoplastic
disorders, or advanced chronic myelogenous leukemia. https://clinicaltrials.gov/ct2/show/NCT02795520June
10–2016
|
|
8
|
simpleClinicalTrials.govSafety study of MELK inhibitor
to treat patients with advanced breast cancer and triple negative
breast cancer. https://clinicaltrials.gov/ct2/show/NCT02926690October
6–2016
|
|
9
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weina K and Utikal J: SOX2 and cancer:
Current research and its implications in the clinic. Clin Transl
Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herreros-Villanueva M, Zhang JS, Koenig A,
Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM,
Bujanda L and Billadeau DD: SOX2 promotes dedifferentiation and
imparts stem cell-like features to pancreatic cancer cells.
Oncogenesis. 2:e612013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bareiss PM, Paczulla A, Wang H, Schairer
R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler
A, et al: SOX2 expression associates with stem cell state in
human ovarian carcinoma. Cancer Res. 73:5544–5555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prior HM and Walter MA: SOX genes:
Architects of development. Mol Med. 2:405–412. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stevanovic M, Zuffardi O, Collignon J,
Lovell-Badge R and Goodfellow P: The cDNA sequence and chromosomal
location of the human SOX2 gene. Mamm Genome. 5:640–642. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou
LJ, Yan H, Ye JW and Liu Y: Expression of MET and SOX2 genes in
non-small cell lung carcinoma with EGFR mutation. Oncol Rep.
26:877–885. 2011.PubMed/NCBI
|
|
16
|
Gen Y, Yasui K, Nishikawa T and Yoshikawa
T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma
through the AKT/mammalian target of rapamycin complex 1 signaling
pathway. Cancer Sci. 104:810–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Z, Pan X, Gao A and Zhu W: Expression
of Sox2 in cervical squamous cell carcinoma. J BUON. 19:203–206.
2014.PubMed/NCBI
|
|
18
|
Sun C, Sun L, Li Y, Kang X, Zhang S and
Liu Y: Sox2 expression predicts poor survival of hepatocellular
carcinoma patients and it promotes liver cancer cell invasion by
activating slug. Med Oncol. 30:5032013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lengerke C, Fehm T, Kurth R, Neubauer H,
Scheble V, Müller F, Schneider F, Petersen K, Wallwiener D, Kanz L,
et al: Expression of the embryonic stem cell marker SOX2 in
early-stage breast carcinoma. BMC Cancer. 11:422011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SH, Oh SY, Do SI, Lee HJ, Kang HJ, Rho
YS, Bae WJ and Lim YC: SOX2 regulates self-renewal and
tumorigenicity of stem-like cells of head and neck squamous cell
carcinoma. Br J Cancer. 111:2122–2130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo W, Li S, Peng B, Ye Y, Deng X and Yao
K: Embryonic stem cells markers SOX2, OCT4 and Nanog expression and
their correlations with epithelial-mesenchymal transition in
nasopharyngeal carcinoma. PLoS One. 8:e563242013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang
X, Jin T, Cai XY, Liang Y, Hu WH, et al: Prognostic significance of
Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma.
J Transl Med. 8:942010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo
RZ, Shao JY, He Z, Zeng YX, Kang T, et al: Prognostic significance
of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest.
30:79–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du L, Yang Y, Xiao X, Wang C, Zhang X,
Wang L, Zhang X, Li W, Zheng G, Wang S, et al: Sox2 nuclear
expression is closely associated with poor prognosis in patients
with histologically node-negative oral tongue squamous cell
carcinoma. Oral Oncol. 47:709–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dai W, Tan X, Sun C and Zhou Q: High
expression of SOX2 is associated with poor prognosis in
patients with salivary gland adenoid cystic carcinoma. Int J Mol
Sci. 15:8393–8406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang XB, Shen XH, Li L, Zhang YF and Chen
GQ: SOX2 overexpression correlates with poor prognosis in laryngeal
squamous cell carcinoma. Auris Nasus Larynx. 40:481–486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonzalez-Marquez R, Llorente JL, Rodrigo
JP, Garcia-Pedrero JM, Alvarez-Marcos C, Suarez C and Hermsen MA:
SOX2 expression in hypopharyngeal, laryngeal, and sinonasal
squamous cell carcinoma. Hum Pathol. 45:851–857. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong Z, Liu G, Huang B, Sun J and Wu D:
Prognostic significance of SOX2 in head and neck cancer: A
meta-analysis. Int J Clin Exp Med. 7:5010–5020. 2014.PubMed/NCBI
|
|
29
|
Chung S, Kijima K, Kudo A, Fujisawa Y,
Harada Y, Taira A, Takamatsu N, Miyamoto T, Matsuo Y and Nakamura
Y: Preclinical evaluation of biomarkers associated with antitumor
activity of MELK inhibitor. Oncotarget. 7:18171–18182. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inoue H, Kato T, Olugbile S, Tamura K,
Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y and Park JH:
Effective growth-suppressive activity of maternal embryonic
leucine-zipper kinase (MELK) inhibitor against small cell lung
cancer. Oncotarget. 7:13621–13633. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato T, Inoue H, Imoto S, Tamada Y,
Miyamoto T, Matsuo Y, Nakamura Y and Park JH: Oncogenic roles of
TOPK and MELK, and effective growth suppression by small molecular
inhibitors in kidney cancer cells. Oncotarget. 7:17652–17664. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stefka AT, Park JH, Matsuo Y, Chung S,
Nakamura Y, Jakubowiak AJ and Rosebeck S: Anti-myeloma activity of
MELK inhibitor OTS167: Effects on drug-resistant myeloma cells and
putative myeloma stem cell replenishment of malignant plasma cells.
Blood Cancer J. 6:e4602016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin A, Giuliano CJ, Sayles NM and Sheltzer
JM: CRISPR/Cas9 mutagenesis invalidates a putative cancer
dependency targeted in on-going clinical trials. Elife.
6:e241792017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wuebben EL and Rizzino A: The dark side of
SOX2: Cancer - A comprehensive overview. Oncotarget. 8:44917–44943.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao X, Sun B, Sun D, Liu T, Che N, Gu Q,
Dong X, Li R, Liu Y and Li J: Slug promotes hepatocellular cancer
cell progression by increasing sox2 and nanog expression. Oncol
Rep. 33:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y,
Liu Y, Lv D, Liu CH, Tan X, et al: SOX2 promotes tumorigenesis and
increases the anti-apoptotic property of human prostate cancer
cell. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tian Y, Jia X, Wang S, Li Y, Zhao P, Cai
D, Zhou Z, Wang J, Luo Y and Dong M: SOX2 oncogenes amplified and
operate to activate AKT signaling in gastric cancer and predict
immunotherapy responsiveness. J Cancer Res Clin Oncol.
140:1117–1124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sanada Y, Yoshida K, Ohara M, Oeda M,
Konishi K and Tsutani Y: Histopathologic evaluation of stepwise
progression of pancreatic carcinoma with immunohistochemical
analysis of gastric epithelial transcription factor S:
Comparison of expression patterns between invasive components and
cancerous or nonneoplastic intraductal components. Pancreas.
32:164–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
